Cargando…
Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma
Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy and adverse...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381560/ https://www.ncbi.nlm.nih.gov/pubmed/35973992 http://dx.doi.org/10.1038/s41420-022-01153-8 |
_version_ | 1784769106442977280 |
---|---|
author | Zhang, Dongmei Zhou, Yunzhen Ma, Yanan Jiang, Ping Lv, Hongchao Liu, Sijia Mu, Yu Zhou, Chong Xiao, Shan Ji, Guohua Liu, Peng Zhang, Ning Sun, Donglin Sun, Haiming Wu, Nan Jin, Yan |
author_facet | Zhang, Dongmei Zhou, Yunzhen Ma, Yanan Jiang, Ping Lv, Hongchao Liu, Sijia Mu, Yu Zhou, Chong Xiao, Shan Ji, Guohua Liu, Peng Zhang, Ning Sun, Donglin Sun, Haiming Wu, Nan Jin, Yan |
author_sort | Zhang, Dongmei |
collection | PubMed |
description | Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy and adverse patient survival. Functional studies indicated RPL22L1 overexpression accelerated cell proliferation, migration, invasion and sorafenib resistance. Mechanism studies revealed that RPL22L1 activated ERK to induce atypical epithelial-to-mesenchymal transition (EMT) progress. Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients. |
format | Online Article Text |
id | pubmed-9381560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93815602022-08-18 Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma Zhang, Dongmei Zhou, Yunzhen Ma, Yanan Jiang, Ping Lv, Hongchao Liu, Sijia Mu, Yu Zhou, Chong Xiao, Shan Ji, Guohua Liu, Peng Zhang, Ning Sun, Donglin Sun, Haiming Wu, Nan Jin, Yan Cell Death Discov Article Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy and adverse patient survival. Functional studies indicated RPL22L1 overexpression accelerated cell proliferation, migration, invasion and sorafenib resistance. Mechanism studies revealed that RPL22L1 activated ERK to induce atypical epithelial-to-mesenchymal transition (EMT) progress. Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients. Nature Publishing Group UK 2022-08-17 /pmc/articles/PMC9381560/ /pubmed/35973992 http://dx.doi.org/10.1038/s41420-022-01153-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhang, Dongmei Zhou, Yunzhen Ma, Yanan Jiang, Ping Lv, Hongchao Liu, Sijia Mu, Yu Zhou, Chong Xiao, Shan Ji, Guohua Liu, Peng Zhang, Ning Sun, Donglin Sun, Haiming Wu, Nan Jin, Yan Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma |
title | Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma |
title_full | Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma |
title_fullStr | Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma |
title_full_unstemmed | Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma |
title_short | Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma |
title_sort | ribosomal protein l22-like1 (rpl22l1) mediates sorafenib sensitivity via erk in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381560/ https://www.ncbi.nlm.nih.gov/pubmed/35973992 http://dx.doi.org/10.1038/s41420-022-01153-8 |
work_keys_str_mv | AT zhangdongmei ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT zhouyunzhen ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT mayanan ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT jiangping ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT lvhongchao ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT liusijia ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT muyu ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT zhouchong ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT xiaoshan ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT jiguohua ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT liupeng ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT zhangning ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT sundonglin ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT sunhaiming ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT wunan ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma AT jinyan ribosomalproteinl22like1rpl22l1mediatessorafenibsensitivityviaerkinhepatocellularcarcinoma |